High GADA titer increases the risk of insulin requirement in LADA patients: A 7-year follow-up (NIRAD study 7)

European Journal of Endocrinology

Volumn 171, Issue 6, 2014, Pages 697-704

  Zampetti, Simona ^a   Campagna, Giuseppe ^a   Tiberti, Claudio ^a   Songini, Marco ^a   Arpi, Maria Luisa ^b   De Simone, Giuseppina ^c   Cossu, Efisio ^d   Cocco, Lorenzo ^e   Osborn, John ^f   Bosi, Emanuele ^g   Giorgino, Francesco ^h   Spoletini, Marialuisa ^f   Buzzetti, Raffaella ^f   Adda, G ⁱ   Di Lembo, S ⁱ   Aglialoro, A ⁱ   Cattaneo, A ⁱ   Scassi, V ⁱ   Anichini, R ⁱ   Arcangeli, A ⁱ   Bardini, R G ⁱ   Basciano, P ⁱ   Bracaccia, M ⁱ   Pistoni, S ⁱ   Bracaglia, D ⁱ   Borzi V ⁱ   Emanuele, V ⁱ   Cannata, F ⁱ   Capitano, G ⁱ   Cignarelli, M ⁱ   Piemontese, S ⁱ   Capuano, G ⁱ   Carro, S ⁱ   Cazzalini, C ⁱ   Ciccarone, A M ⁱ   Cicioni, G ⁱ   Sano, F ⁱ   Cucinotta, D ⁱ   Di Benedetto, A ⁱ   De Mattia, G ⁱ   Mollica, M R ⁱ   De Cosmo, S ⁱ   Minenna, A ⁱ   Dei Cas, A ⁱ   Di Berardino, P ⁱ   Dotta, F ⁱ   Contini, V ⁱ   Franzetti, I ⁱ   Frontoni, S ⁱ   Gadaleta, G ⁱ   Galeone, G ⁱ   Magiar, A V ⁱ   Garofano, M R ⁱ   Gentile, S ⁱ   Guarino, G ⁱ   Giansanti, R ⁱ   Genovese, S ^i,i   Giancaterini, A ⁱ   Leotta, S ⁱ   Gianni, E ⁱ   Burrafato, S ⁱ   Giordano, C ^i,i   Gigante, A ⁱ   Cicalo, A ⁱ   Gnasso, A ⁱ   Fiaschi, E ⁱ   Grossi, G ⁱ   Deverardinis, F ⁱ   Ianni, L ⁱ   Iovine, C ⁱ   Lauro, R ⁱ   Federici, M ⁱ   Spallone, V ^i,i   Lo Presti, A ⁱ   Scarpetta, A M ⁱ   Lunari, R ⁱ   Manna, R ⁱ   Margotta, A ⁱ   Mantovani, E ⁱ   Matteoli, M C ⁱ   Matteucci, E ⁱ   Chiesi, F ⁱ   Maran, A ⁱ   Mascetti, P ⁱ   Quintana, T ⁱ   Mazzucca, P ⁱ   Melga, P ⁱ   Cordera, R ⁱ   Meloncelli, I ⁱ   Morano, S ⁱ   Morviducci, L ⁱ   Nannipieri, M ⁱ   Parillo, M ⁱ   Pacifico, A ⁱ   Pascal, G ⁱ   Papini, E ⁱ   Graziano, F ⁱ   Passaro, A ⁱ   Pata, P ⁱ   Pontiroli, A E ⁱ   Pozzilli, P ⁱ   Cipolloni, L ⁱ   Guglielmi, C ⁱ   Puccio, L ⁱ   Raffa, L M ⁱ   Richini, D ⁱ   Romano, R ⁱ   Rotella, C ⁱ   Santantonio, G ⁱ   Sbriglia, M S ⁱ   Cau, V ⁱ   Scorsone, A ⁱ   Taboga, C ⁱ   Tatti, P ⁱ   Turco, A ⁱ   Trovati, M ⁱ   Fiori, E ⁱ   Vasta, M ⁱ   Vitale, F ⁱ   Zavaroni, D ⁱ   Giaccari, A ⁱ   Di Pietro, S ⁱ   Suraci, C ⁱ   Locatelli, M ⁱ   Bazzigaluppi, E ⁱ   Falorni, A ⁱ   Capizzi, M ⁱ   Marandola, L ⁱ   Petrone, A ⁱ   more..

^a San Michele Hospital   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c Diabetologic Center   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e Hospital 'A Cardarelli'   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; INSULIN SENSITIZING AGENT; PROTEIN TYROSINE PHOSPHATASE IA 21C ANTIBODY; SULFONYLUREA; UNCLASSIFIED DRUG; ZINC TRANSPORTER; ZINC TRANSPORTER 8; ANTIDIABETIC AGENT; AUTOANTIBODY; GLUTAMATE DECARBOXYLASE;

ADULT; ANTIBODY TITER; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DIET THERAPY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INSULIN TREATMENT; KAPLAN MEIER METHOD; LATENT AUTOIMMUNE DIABETES IN ADULT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; AGED; BLOOD; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; IMMUNOLOGY; MIDDLE AGED; RISK; TITRIMETRY;

ADULT; AGED; AUTOANTIBODIES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLUTAMATE DECARBOXYLASE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RISK; TITRIMETRY;

EID: 84911982531     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0342     Document Type: Article

References (35)

1. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF&Holman R. UKPDS 25: autoantibodies to isletcell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes: UK Prospective Diabetes Study Group. Lancet 1997 350 1288-1293. (doi:10.1016/S0140-6736(97)03062-6)
2. Bottazzo GF, Bosi E,Cull CA, Bonifacio E, Locatelli M,Zimmet P,Mackay IR & Holman RR. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005 48 703-708. (doi:10.1007/s00125-005-1691-9)
3. Trabucchi A, Faccinetti NI, Guerra LL, Puchulu FM, Frechtel GD, Poskus E & Valdez SN. Detection and characterization of ZnT8 autoantibodies could help to screen latent autoimmune diabetes in adult-onset patients with type 2 phenotype. Autoimmunity 2012 45 137-142. (doi:10.3109/08916934.2011.604658)
4. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W & Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993 42 359-362. (doi:10.2337/diab.42.2.359)
5. Akesson C, Uvebrant K, Oderup C, Lynch K, Harris RA, Lernmark A, Agardh CD & Cilio CM. Altered natural killer (NK) cell frequency and phenotype in latent autoimmune diabetes in adults (LADA) prior to insulin deficiency. Clinical and Experimental Immunology 2010 161 48-56. (doi:10.1111/j.1365-2249.2010.04114.x)
6. Maioli M, Pes GM, Delitala G, Puddu L, Falorni A, Tolu F, Lampis R, Orrù V, Secchi G, Cicalò AM et al. Number of autoantibodies and HLA genotype, more than high titers of glutamic acid decarboxylase autoantibodies, predict insulin dependence in latent autoimmune diabetes of adults. European Journal of Endocrinology 2010 163 541-549. (doi:10.1530/EJE-10-0427)
7. Gottsäter A, Landin-Olsson M, Lernmark A, Fernlund P, Sundkvist G & Hagopian WA. Glutamate decarboxylase antibody levels predict rate of b-cell decline in adult-onset diabetes. Diabetes Research and Clinical Practice 1995 27 133-140.
8. Niskanen LK, Tuomi T, Karjalainen J, Groop LC & Uusitupa MI. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 1995 18 1557-1565. (doi:10.2337/diacare.18.12.1557)
9. Radtke MA, Midthjell K, Nilsen TI & Grill V. Heterogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment: results from the Nord-Trøndelag Health (HUNT) study. Diabetes Care 2009 32 245-250. (doi:10.2337/dc08-1468)
10. Genovese S, Bazzigaluppi E, GonçalvesD, Ciucci A, Cavallo MG, Purrello F, Anello M, Rotella CM, Bardini G, Vaccaro O et al. Clinical phenotype and b-cell autoimmunity in Italian patientswith adult-onset diabetes. European Journal of Endocrinology 2006 154 441-447. (doi:10.1530/eje.1.02115)
11. Maruyama T, Nakagawa T, Kasuga A & Murata M. Heterogeneity among patients with latent autoimmune diabetes in adults. Diabetes/Metabolism Research and Reviews 2011 27 971-974. (doi:10.1002/dmrr.1238)
12. Desai M, Cull CA, Horton VA, Christie MR, Bonifacio E, Lampasona V, Bingley PJ, Levy JC, Mackay IR, Zimmet P et al. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia 2007 50 2052-2060. (doi:10.1007/s00125-007-0745-6)
13. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML, Bazzigaluppi E, Dotta F et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 2007 30 932-938. (doi:10.2337/dc06-1696)
14. Zampetti S, Capizzi M, Spoletini M, Campagna G, Leto G, Cipolloni L, Tiberti C, Bosi E, Falorni A, Buzzetti R et al. GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6). Journal of Clinical Endocrinology and Metabolism 2012 97 3759-3765. (doi:10.1210/jc.2012-2037)
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006 29 S43-S48.
16. Bonifacio E, Genovese S, Braghi S, Bazzigaluppi E, Lampasona V, Bingley PJ, Rogge L, Pastore MR, Bognetti E, Bottazzo GF et al. Islet autoantibodymarkers in insulin dependent diabetes: risk assessment strategies yielding high sensitivity. Diabetologia 1995 38 816-822. (doi:10.1007/s001250050358)
17. Bingley PJ, Bonifacio E & Mueller PW. Diabetes antibody standardization program: first assay proficiency evaluation. Diabetes 2003 52 1128-1136. (doi:10.2337/diabetes.52.5.1128)
18. Lampasona V, Petrone A, Tiberti C, Capizzi M, Spoletini M, Di Pietro S, SonginiM, Bonicchio S, Giorgino F, Bonifacio E et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes. Non-insulin requiring autoimmune diabetes (NIRAD) 4. Diabetes Care 2010 33 104-108. (doi:10.2337/dc08-2305)
19. Buzzetti R, Galgani A, Petrone A, Del Buono ML, Erlich HA, Bugawan TL, Lorini R,Meschi F, Multari G, Pozzilli P et al.Genetic prediction of type 1 diabetes in a population with low frequency of HLA risk genotypes and low incidence of the disease (the DIABFIN study). Diabetes/Metabolism Research and Reviews 2004 2 137-143. (doi:10.1002/dmrr.426)
20. Petrone A, Bugawan TL, Mesturino CA, Nisticò L, Galgani A, Giorgi G, Cascino I, Erlich HA, Di Mario U & Buzzetti R. The distribution of HLA class II susceptible/protective haplotypes could partially explain the low incidence of type 1 diabetes in continental Italy (Lazio region). Tissue Antigens 2001 58 385-394. (doi:10.1034/j.1399-0039.2001.580607.x)
21. Lee SA, Lee WJ, Kim EH, Yu JH, Jung CH, Koh EH, Kim MS, Park JY & Lee KU. Progression to insulin deficiency in Korean patients with type 2 diabetes mellitus positive for anti-GAD antibody. Diabetic Medicine 2011 28 319-324. (doi:10.1111/j.1464-5491.2011.03241.x)
22. Davis TM, Zimmet P, Davis WA, Bruce DG, Fida S & Mackay IR. Autoantibodies to glutamic acid decarboxylase in diabetic patients froma multi-ethnic Australian community: the Fremantle diabetes study. Diabetic Medicine 2000 17 667-674. (doi:10.1046/j.1464-5491.2000.00359.x)
23. Brophy S, Yderstraede K, Mauricio D, Hunter S, Hawa M, Pozzilli P, Schernthaner G, Schloot N, Buzzetti R, Davies H et al. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 2008 31 439-441. (doi:10.2337/dc07-1308)
24. Falorni A & Brozzetti A. Diabetes-related antibodies in adult diabetic patients. Best Practice & Research. Clinical Endocrinology & Metabolism 2005 19 119-133. (doi:10.1016/j.beem.2004.11.010)
25. Kasuga A, Maruyama T, Nakamoto S, Ozawa Y, Suzuki Y & Saruta T. High titer autoantibodies against glutamic acid decarboxylase plus autoantibodies against insulin and IA-2 predicts insulin requirement in adult diabetic patients. Journal of Autoimmunity 1999 12 131-135. (doi:10.1006/jaut.1998.0261)
26. Takeda H, Kawasaki E, Shimizu I, Konoue E, Fujiyama M, Murao S, Tanaka K, Mori K, Tarumi Y, Seto I et al. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care 2002 25 995-1001. (doi:10.2337/diacare.25.6.995)
27. Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, Mauricio D, De Leiva A, Yderstraede K, Beck-Neilsen H et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013 36 908-913. (doi:10.2337/dc12-0931)
28. Borg H, Gottsäter A, Fernlund P & Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and b-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002 51 1754-1762. (doi:10.2337/diabetes.51.6.1754)
29. Kawasaki E, Nakamura K, Kuriya G, Satoh T, Kuwahara H, KobayashiM, Abiru N, Yamasaki H & Eguchi K. Autoantibodies to insulin, insulinoma-associated antigen-2, and zinc transporter 8 improve the prediction of early insulin requirement in adult-onset autoimmune diabetes. Journal of Clinical Endocrinology and Metabolism 2010 95 707-713. (doi:10.1210/jc.2009-1733)
30. Lohmann T, Kellner K, Verlohren HJ, Krug J, Steindorf J, ScherbaumWA & Seissler J. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 2001 44 1005-1010. (doi:10.1007/s001250100602)
31. Li X, Huang G, Yan X, Yang L & Zhou ZG. Relation between insulin resistance and glutamic acid decarboxylase antibody titers in latent autoimmune diabetes in adults. J Nan Fang Yi Ke Da Xue Xue Bao 2010 30 1247-1249.
32. Cernea S, Buzzetti R & Pozzilli P. β-cell protection and therapy for latent autoimmune diabetes in adults. Diabetes Care 2009 32 (Suppl 2) S246-S252. (doi:10.2337/dc09-S317)
33. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T & Donath MY. Sulfonylurea induced b-cell apoptosis in cultured human islets. Journal of Clinical Endocrinology and Metabolism 2005 90 501-506. (doi:10.1210/jc.2004-0699)
34. Yang Z, Zhou Z, Li X, Huang G & Lin J. Rosiglitazone preserves islet β-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Research and Clinical Practice 2009 83 54-60. (doi:10.1016/j.diabres.2008.09.044)
35. Maruyama T, Shimada A, Kanatsuka A, Kasuga A, Takei I, Yokoyama J & Kobayashi T. Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Annals of New York Academy of Sciences 2003 1005 362-369. (doi:10.1196/annals.1288.060)